AR105485A1 - Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo - Google Patents
Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismoInfo
- Publication number
- AR105485A1 AR105485A1 ARP160101975A ARP160101975A AR105485A1 AR 105485 A1 AR105485 A1 AR 105485A1 AR P160101975 A ARP160101975 A AR P160101975A AR P160101975 A ARP160101975 A AR P160101975A AR 105485 A1 AR105485 A1 AR 105485A1
- Authority
- AR
- Argentina
- Prior art keywords
- cysteine
- absent
- valine
- glutamic acid
- arginine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Desarrollo de variantes de glucagón para mejorar los efectos terapéuticos en la hipoglucemia y obesidad. Estas variantes de glucagón presentan solubilidad y estabilidad alta a pH neutro. Reivindicación 1: Una composición farmacéutica para el tratamiento o la prevención de síndromes metabólicos que comprende i) un péptido que comprende la secuencia de aminoácidos de la fórmula general (1), y ii) al menos un compuesto o material que tiene una actividad terapéutica para el síndrome metabólico, X¹-X²-QGTF-X⁷-SD-X¹⁰-S-X¹²-X¹³-X¹⁴-X¹⁵-X¹⁶-X¹⁷-X¹⁸-X¹⁹-X²⁰-X²¹-F-X²³-X²⁴-W-L-X²⁷-X²⁸-X²⁹-X³⁰ (fórmula general (1), SEQ ID Nº: 45) en la que, en la fórmula general (1), X¹ es histidina, desamino-histidil, N-dimetil-histidil, b-hidroxi imidazopripionilo, 4-imidazoacetilo, b-carboxi imidazopropionilo, triptófano o tirosina, o está ausente; X² es ácido a-metil-glutámico, ácido aminoisobutírico (Aib), D-alanina, glicina, Sar(N-metilglicina), serina o D-serina; X⁷ es treonina, valina o cisteína; X¹⁰ es tirosina o cisteína; X¹² es lisina o cisteína; X¹³ es tirosina o cisteína; X¹⁴ es leucina o cisteína; X¹⁵ es ácido aspártico, ácido glutámico o cisteína; X¹⁶ es ácido glutámico, ácido aspártico, serina, ácido a-metil-glutámico, o cisteína, o está ausente; X¹⁷ es ácido aspártico, glutamina, ácido glutámico, lisina, arginina, serina, cisteína o valina, o está ausente; X¹⁸ es alanina, ácido aspártico, ácido glutámico, arginina, valina o cisteína, o está ausente; X¹⁹ es alanina, arginina, serina, valina o cisteína, o está ausente; X²⁰ es lisina, histidina, glutamina, ácido aspártico, lisina, arginina, ácido a-metil-glutámico o cisteína, o está ausente; X²¹ es ácido aspártico, ácido glutámico, leucina; valina o cisteína, o está ausente; X²³ es isoleucina, valina y arginina, o está ausente; X²⁴ es valina, arginina, alanina, cisteína, ácido glutámico, lisina, glutamina, ácido a-metil-glutámico, o leucina, o está ausente; X²⁷ es isoleucina, valina, alanina, lisina, metionina, glutamina, o arginina, o está ausente; X²⁸ es glutamina, lisina, asparagina o arginina o está ausente; X²⁹ es lisina, alanina, glicina, o treonina, o está ausente; y X³⁰ es cisteína, o está ausente; con la condición de que cuando la secuencia de aminoácidos de la fórmula general (1) es idéntica a la SEQ ID Nº 1, se excluye.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150093265 | 2015-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR105485A1 true AR105485A1 (es) | 2017-10-11 |
Family
ID=57608802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101975A AR105485A1 (es) | 2015-06-30 | 2016-06-29 | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo |
Country Status (29)
Country | Link |
---|---|
US (3) | US10696725B2 (es) |
EP (2) | EP4324519A2 (es) |
JP (3) | JP6882210B2 (es) |
KR (2) | KR102005456B1 (es) |
CN (1) | CN108025041A (es) |
AR (1) | AR105485A1 (es) |
AU (2) | AU2016287209B2 (es) |
BR (1) | BR112017028517A2 (es) |
CA (1) | CA2991107A1 (es) |
CL (5) | CL2017003402A1 (es) |
CO (1) | CO2018000303A2 (es) |
CR (1) | CR20180034A (es) |
DK (1) | DK3322437T3 (es) |
DO (1) | DOP2017000318A (es) |
EA (1) | EA201890058A1 (es) |
EC (1) | ECSP18003879A (es) |
FI (1) | FI3322437T3 (es) |
HK (1) | HK1248129A1 (es) |
IL (2) | IL256619B (es) |
MA (2) | MA49545B1 (es) |
MX (1) | MX2017016845A (es) |
PE (1) | PE20180449A1 (es) |
PH (1) | PH12017502393A1 (es) |
PT (1) | PT3322437T (es) |
TN (1) | TN2017000555A1 (es) |
TW (1) | TWI713541B (es) |
UA (1) | UA127445C2 (es) |
UY (1) | UY36759A (es) |
WO (1) | WO2017003191A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー/エス | 医療用のglp−1/グルカゴン受容体コアゴニスト |
TW201639878A (zh) | 2014-12-30 | 2016-11-16 | 韓美藥品股份有限公司 | 具有改善之安定性的升糖素衍生物 |
AU2016287209B2 (en) | 2015-06-30 | 2023-03-02 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
PT3398961T (pt) | 2015-12-31 | 2022-09-05 | Hanmi Pharm Ind Co Ltd | Ativador triplo ativando recetor glucagon, glp-1 e gip |
NZ750267A (en) * | 2016-06-29 | 2023-12-22 | Hanmi Pharm Ind Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
KR102645064B1 (ko) * | 2017-02-03 | 2024-03-08 | 한미약품 주식회사 | 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도 |
CN110545852B (zh) | 2017-02-07 | 2023-05-26 | 韩美药品株式会社 | 非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法 |
US20200283492A1 (en) * | 2017-09-29 | 2020-09-10 | Hanmi Pharm Co., Ltd. | Long acting protein complex having an enhanced efficiency |
CN112912095A (zh) | 2018-07-19 | 2021-06-04 | D&D制药技术股份有限公司 | 包括多肽的药物组合物 |
WO2020017919A1 (ko) * | 2018-07-19 | 2020-01-23 | 한미정밀화학주식회사 | 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법 |
KR101990075B1 (ko) * | 2018-07-19 | 2019-06-18 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물 |
KR20200135618A (ko) * | 2019-05-23 | 2020-12-03 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물 |
BR112021006477A2 (pt) * | 2018-10-04 | 2021-07-13 | Hanmi Pharm. Co., Ltd. | combinação que compreende uma substância com atividade para um receptor de glucagon ou um conjugado do mesmo, kit e composição farmacêutica para prevenir ou tratar doenças |
CN109239346B (zh) * | 2018-10-31 | 2019-10-11 | 中国药科大学 | 一组代谢标志物在代谢综合征早期诊断方面的应用 |
WO2020130751A1 (ko) | 2018-12-21 | 2020-06-25 | 한미약품 주식회사 | 인슐린 및 글루카곤을 포함하는 약학 조성물 |
TW202114728A (zh) * | 2019-06-28 | 2021-04-16 | 南韓商韓美藥品股份有限公司 | 三重升糖素/glp-1/gip受體促效劑或其接合物用於肝臟疾病之治療用途 |
KR20210040818A (ko) * | 2019-10-04 | 2021-04-14 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
CN110845601B (zh) * | 2019-10-12 | 2021-01-19 | 广东药科大学 | 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用 |
US20210290732A1 (en) * | 2020-02-21 | 2021-09-23 | Spitfire Pharma Llc | GLP-1R and GCGR Agonists, Formulations, and Methods of Use |
KR20210144606A (ko) * | 2020-05-22 | 2021-11-30 | 한미약품 주식회사 | 글루카곤 유도체의 지속형 결합체의 액상 제제 |
EP4183407A1 (en) * | 2020-07-15 | 2023-05-24 | Hanmi Pharm. Co., Ltd. | Therapeutic use of glucagon derivative or conjugate thereof for liver disease |
CA3188884A1 (en) * | 2020-08-14 | 2022-02-17 | Seungjae Baek | Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors |
KR20220140443A (ko) * | 2021-04-09 | 2022-10-18 | 한미약품 주식회사 | 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물 |
KR20230095666A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
WO2005047336A1 (en) * | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical. Co. Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
PL1605897T3 (pl) | 2003-03-19 | 2012-12-31 | Lilly Co Eli | Związki będące połączeniem GLP-1 z poli(glikolem etylenowym) |
US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
WO2007124461A2 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compounds |
US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
AU2008205229B2 (en) | 2007-01-05 | 2014-03-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
US7994122B2 (en) | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
CA2696615A1 (en) | 2007-06-19 | 2008-12-24 | Otsuka Chemical Co., Ltd. | Oligosaccharide chain added glp-1 peptide |
EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
PL2300035T3 (pl) | 2008-06-17 | 2016-04-29 | Univ Indiana Res & Tech Corp | Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości |
MX2010012695A (es) * | 2008-06-17 | 2011-03-15 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. |
EP2300037B1 (en) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
KR20120087875A (ko) * | 2009-06-16 | 2012-08-07 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체-활성 글루카곤 화합물 |
HUE026255T2 (en) * | 2009-07-13 | 2016-06-28 | Zealand Pharma As | Acylated glucagon analogues |
GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
US8703701B2 (en) * | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
KR20120128129A (ko) | 2010-01-20 | 2012-11-26 | 질랜드 파마 에이/에스 | 심장 병태의 치료 |
KR20130018410A (ko) * | 2010-03-26 | 2013-02-21 | 노보 노르디스크 에이/에스 | 새로운 글루카곤 유사체 |
CN103179976A (zh) | 2010-05-13 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 呈现g蛋白偶联受体活性的胰高血糖素超家族肽 |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
KR20230023059A (ko) | 2011-05-18 | 2023-02-16 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
PT2718318T (pt) | 2011-06-10 | 2018-11-09 | Hanmi Science Co Ltd | Derivados de oxintomodulina inovadores e composição farmacêutica para tratar a obesidade compreendendo os mesmos |
PE20181268A1 (es) | 2011-06-17 | 2018-08-03 | Hanmi Science Co Ltd | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y el uso del mismo |
US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
JP6324315B2 (ja) | 2011-11-17 | 2018-05-16 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
WO2013120022A2 (en) | 2012-02-08 | 2013-08-15 | Seneb Biosciences, Inc. | Treatment of hypoglycemia |
CN107739409A (zh) | 2012-05-18 | 2018-02-27 | 爱德迪安(北京)生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
PE20150863A1 (es) | 2012-06-21 | 2015-06-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad de receptor de gip |
CA2877358A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
PT2916819T (pt) | 2012-11-06 | 2019-10-28 | Hanmi Pharm Ind Co Ltd | Formulação líquida de conjugado proteico que compreende a oxintomodulina e um fragmento de imunoglobulina. |
DK2922876T3 (en) | 2012-11-20 | 2019-02-04 | Mederis Diabetes Llc | IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE |
EP4047023A1 (en) | 2012-11-20 | 2022-08-24 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
HUE038748T2 (hu) | 2012-12-21 | 2018-11-28 | Sanofi Sa | Exendin-4 származékok, mint duális GLP1/GIP- vagy trigonális GLP1/GIP/glukagon-agonisták |
RS59124B1 (sr) | 2013-04-18 | 2019-09-30 | Novo Nordisk As | Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu |
WO2015022420A1 (en) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
KR102455171B1 (ko) | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
ES2822994T3 (es) | 2014-09-24 | 2021-05-05 | Univ Indiana Res & Tech Corp | Conjugados de incretina-insulina |
CN107106680A (zh) * | 2014-11-13 | 2017-08-29 | 江苏奥赛康药业股份有限公司 | 具备双受体激动剂活性的融合蛋白 |
TW201639878A (zh) | 2014-12-30 | 2016-11-16 | 韓美藥品股份有限公司 | 具有改善之安定性的升糖素衍生物 |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
AU2016287209B2 (en) | 2015-06-30 | 2023-03-02 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
US20170004368A1 (en) | 2015-07-05 | 2017-01-05 | Neteera Technologies Ltd. | System and method for biometric detection based on sweat ducts |
TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物 |
EP3384935A4 (en) | 2015-12-02 | 2019-08-21 | Hanmi Pharm. Co., Ltd. | PROTEIN COMPLEX UTILIZING A FATTY ACID DERIVATIVE, AND PROCESS FOR PREPARING THE SAME |
PT3398961T (pt) | 2015-12-31 | 2022-09-05 | Hanmi Pharm Ind Co Ltd | Ativador triplo ativando recetor glucagon, glp-1 e gip |
-
2016
- 2016-06-29 AU AU2016287209A patent/AU2016287209B2/en active Active
- 2016-06-29 FI FIEP16818224.4T patent/FI3322437T3/fi active
- 2016-06-29 PT PT168182244T patent/PT3322437T/pt unknown
- 2016-06-29 UA UAA201800030A patent/UA127445C2/uk unknown
- 2016-06-29 KR KR1020160081976A patent/KR102005456B1/ko active IP Right Grant
- 2016-06-29 TW TW105120481A patent/TWI713541B/zh active
- 2016-06-29 EP EP23214927.8A patent/EP4324519A2/en active Pending
- 2016-06-29 TN TNP/2017/000555A patent/TN2017000555A1/en unknown
- 2016-06-29 CN CN201680048764.5A patent/CN108025041A/zh active Pending
- 2016-06-29 EA EA201890058A patent/EA201890058A1/ru unknown
- 2016-06-29 US US15/740,668 patent/US10696725B2/en active Active
- 2016-06-29 JP JP2017568076A patent/JP6882210B2/ja active Active
- 2016-06-29 CA CA2991107A patent/CA2991107A1/en active Pending
- 2016-06-29 EP EP16818224.4A patent/EP3322437B1/en active Active
- 2016-06-29 CR CR20180034A patent/CR20180034A/es unknown
- 2016-06-29 UY UY0001036759A patent/UY36759A/es unknown
- 2016-06-29 MA MA49545A patent/MA49545B1/fr unknown
- 2016-06-29 BR BR112017028517-7A patent/BR112017028517A2/pt active Search and Examination
- 2016-06-29 AR ARP160101975A patent/AR105485A1/es unknown
- 2016-06-29 PE PE2017002855A patent/PE20180449A1/es unknown
- 2016-06-29 MA MA41887A patent/MA41887B1/fr unknown
- 2016-06-29 MX MX2017016845A patent/MX2017016845A/es unknown
- 2016-06-29 WO PCT/KR2016/006984 patent/WO2017003191A1/en active Application Filing
- 2016-06-29 DK DK16818224.4T patent/DK3322437T3/da active
-
2017
- 2017-12-21 PH PH12017502393A patent/PH12017502393A1/en unknown
- 2017-12-27 IL IL256619A patent/IL256619B/en unknown
- 2017-12-27 CL CL2017003402A patent/CL2017003402A1/es unknown
- 2017-12-28 DO DO2017000318A patent/DOP2017000318A/es unknown
-
2018
- 2018-01-15 CO CONC2018/0000303A patent/CO2018000303A2/es unknown
- 2018-01-18 EC ECIEPI20183879A patent/ECSP18003879A/es unknown
- 2018-06-14 HK HK18107718.6A patent/HK1248129A1/zh unknown
-
2019
- 2019-07-24 KR KR1020190089584A patent/KR102395855B1/ko active IP Right Grant
-
2020
- 2020-03-06 US US16/812,011 patent/US11261227B2/en active Active
-
2021
- 2021-03-05 JP JP2021034966A patent/JP2021102618A/ja active Pending
-
2022
- 2022-01-14 US US17/576,519 patent/US11667688B2/en active Active
- 2022-03-13 IL IL291291A patent/IL291291B2/en unknown
-
2023
- 2023-01-20 CL CL2023000198A patent/CL2023000198A1/es unknown
- 2023-02-13 JP JP2023019975A patent/JP2023062043A/ja active Pending
- 2023-02-24 AU AU2023201118A patent/AU2023201118A1/en active Pending
- 2023-06-27 CL CL2023001911A patent/CL2023001911A1/es unknown
- 2023-06-27 CL CL2023001910A patent/CL2023001910A1/es unknown
- 2023-06-27 CL CL2023001909A patent/CL2023001909A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR105485A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
AR103322A1 (es) | Derivados de glucagón con estabilidad mejorada | |
PE20190355A1 (es) | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo | |
AR086866A1 (es) | Derivados de oxintomodulina y composicion farmaceutica que los comprende para el tratamiento de la obesidad | |
AR086969A1 (es) | Conjugado que comprende oxontomodulina y un fragmento de inmunoglobulina, y su uso | |
PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
CO6220904A2 (es) | Acidos nucleicos que codifican mutantes de acetohidroxiacido-sintasa (ahas) | |
UY37998A (es) | Agentes antivirales contra la hepatitis b | |
EA201992247A1 (ru) | Быстрая и контролируемая доставка композиций с восстановленным эффектом антуража | |
CL2016001405A1 (es) | A peptide mixture | |
JP2018504901A5 (es) | ||
EA201991065A1 (ru) | Вакцина против свиного парвовируса | |
BR112021023957A2 (pt) | Peptídeos | |
AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
MX2017006748A (es) | Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades. | |
NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
BR112015032556A2 (pt) | Proteína matriz (m) modificada de um vírus da estomatite vesicular (vsv); sequência de nucleotídeos que codifica uma proteína matriz modificada de um vírus da estomatite vesicular; vírus da estomatite vesicular recombinante (rvsv); vacina; vacina de combinação de preparação e reforço; kit; peptídeo isolado; sequências de nucleotídeos isoladas; uso da vacina; uso da vacina de combinação de preparação e reforço; método para induzir uma resposta imunológica em um indivíduo | |
NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
ES2527527T3 (es) | Composiciones basadas en aminoácidos de cadena ramificada para mejorar la función ventricular miocárdica en pacientes que padecen diabetes | |
MY187022A (en) | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy | |
AR109799A1 (es) | Composición para el tratamiento del cabello | |
BR112018071215A2 (pt) | peptídeo para uso no tratamento, melhora ou prevenção de osteoartrite | |
AR108969A1 (es) | Derivado de glucagón, un conjugado del mismo, y una composición que comprende el mismo, y un uso terapéutico del mismo | |
CR20180008A (es) | Variantes de il-37 |